SHR-A2102 not checked

Hengrui

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
12 active
15 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Treatment with SHR-A2102 in combination with fixed dose Adebrelimab.”In the company’s words, NCT06879145 on ClinicalTrials.gov
Tested for
Advanced Solid Tumors (3 trials), Advanced Urothelial Carcinoma (2 trials), Recurrent Cervical Cancer, Metastatic Cervical Cancer, Muscular Invasive Bladder Cancer (MIBC), Non-small Cell Lung Cancer, Advanced Malignant Tumour, Advanced or Metastatic Non-small Cell Lung Cancer and 2 more
Main trialPhase 3
“To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.”In the company’s words, NCT06738251 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumors

All 2440 drugs for Advanced Solid Tumors

Coming up8

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials15

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jul 2026 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Phase 3Recruiting Dec 2027 A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Phase 2/3Recruiting Dec 2031 Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Phase 2Recruiting Oct 2026 A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Phase 2Recruiting Dec 2026 A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
Phase 2Recruiting Dec 2028 A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Phase 1/2Recruiting Oct 2026 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1/2Recruiting Mar 2027 A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Phase 1/2Recruiting 31 May 2027 A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Phase 1/2Recruiting 31 Dec 2031 A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Phase 1Recruiting 31 Aug 2025 Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
Phase 1Not yet recruiting 30 Apr 2027 A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
Phase 2Unknown 31 Aug 2025 A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
Phase 1/2Unknown 30 Apr 2026 A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1Unknown 31 Aug 2025 A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SHR-A2102

Following is part of Solo: you see every change to SHR-A2102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in